ProShare Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $38.7M | Sell |
128,514
-45,499
| -26% | -$13.7M | 0.06% | 180 |
|
|
2026
Q1 | $57.6M | Sell |
174,013
-37,064
| -18% | -$12.6M | 0.09% | 153 |
|
|
2025
Q4 | $83.9M | Buy |
211,077
+206,446
| +4,458% | +$91.4M | 0.15% | 148 |
|
|
2025
Q3 | $2.11M | Buy |
4,631
+390
| +9% | +$159K | ﹤0.01% | 689 |
|
|
2025
Q2 | $1.38M | Sell |
4,241
-1,599
| -27% | -$442K | ﹤0.01% | 732 |
|
|
2025
Q1 | $1.58M | Sell |
5,840
-270
| -4% | -$69.4K | ﹤0.01% | 707 |
|
|
2024
Q4 | $1.44M | Sell |
6,110
-1,476
| -19% | -$388K | ﹤0.01% | 777 |
|
|
2024
Q3 | $2.09M | Sell |
7,586
-223
| -3% | -$58.1K | 0.01% | 671 |
|
|
2024
Q2 | $1.9M | Sell |
7,809
-1,018
| -12% | -$161K | 0.01% | 674 |
|
|
2024
Q1 | $1.32M | Buy |
8,827
+809
| +10% | +$135K | ﹤0.01% | 734 |
|
|
2023
Q4 | $1.53M | Sell |
8,018
-154
| -2% | -$26.2K | ﹤0.01% | 686 |
|
|
2023
Q3 | $1.45M | Buy |
8,172
+115
| +1% | +$21.9K | ﹤0.01% | 678 |
|
|
2023
Q2 | $1.53M | Sell |
8,057
-757
| -9% | -$150K | ﹤0.01% | 680 |
|
|
2023
Q1 | $1.77M | Sell |
8,814
-3,227
| -27% | -$678K | 0.01% | 662 |
|
|
2022
Q4 | $2.86M | Buy |
12,041
+33
| +0.3% | +$7.04K | 0.01% | 554 |
|
|
2022
Q3 | $2.4M | Buy |
12,008
+619
| +5% | +$118K | 0.01% | 589 |
|
|
2022
Q2 | $1.66M | Sell |
11,389
-3,801
| -25% | -$539K | 0.01% | 673 |
|
|
2022
Q1 | $2.48M | Sell |
15,190
-4,656
| -23% | -$709K | 0.01% | 685 |
|
|
2021
Q4 | $3.37M | Sell |
19,846
-8,361
| -30% | -$1.55M | 0.01% | 652 |
|
|
2021
Q3 | $5.33M | Buy |
28,207
+2,838
| +11% | +$532K | 0.02% | 505 |
|
|
2021
Q2 | $4.3M | Buy |
25,369
+6,983
| +38% | +$1.02M | 0.01% | 525 |
|
|
2021
Q1 | $2.6M | Sell |
18,386
-1,631
| -8% | -$245K | 0.01% | 619 |
|
|
2020
Q4 | $2.6M | Sell |
20,017
-677
| -3% | -$90.4K | 0.01% | 574 |
|
|
2020
Q3 | $3.01M | Buy |
20,694
+522
| +3% | +$74.2K | 0.01% | 485 |
|
|
2020
Q2 | $2.99M | Buy |
20,172
+2,783
| +16% | +$375K | 0.02% | 479 |
|
|
2020
Q1 | $1.89M | Sell |
17,389
-9,386
| -35% | -$1.08M | 0.01% | 498 |
|
|
2019
Q4 | $3.08M | Sell |
26,775
-5,944
| -18% | -$593K | 0.01% | 531 |
|
|
2019
Q3 | $2.63M | Sell |
32,719
-677
| -2% | -$53.6K | 0.01% | 533 |
|
|
2019
Q2 | $2.42M | Sell |
33,396
-6,523
| -16% | -$500K | 0.01% | 552 |
|
|
2019
Q1 | $3.73M | Buy |
39,919
+3,032
| +8% | +$254K | 0.02% | 474 |
|
|
2018
Q4 | $2.69M | Sell |
36,887
-7,327
| -17% | -$564K | 0.02% | 514 |
|
|
2018
Q3 | $3.87M | Sell |
44,214
-19
| -0% | -$1.91K | 0.03% | 478 |
|
|
2018
Q2 | $4.36M | Sell |
44,233
-4,032
| -8% | -$400K | 0.03% | 463 |
|
|
2018
Q1 | $5.75M | Sell |
48,265
-7,365
| -13% | -$949K | 0.04% | 414 |
|
|
2017
Q4 | $7.07M | Buy |
55,630
+2,152
| +4% | +$270K | 0.05% | 362 |
|
|
2017
Q3 | $6.28M | Buy |
53,478
+4,973
| +10% | +$424K | 0.06% | 330 |
|
|
2017
Q2 | $3.87M | Buy |
48,505
+1,078
| +2% | +$68.9K | 0.04% | 404 |
|
|
2017
Q1 | $2.43M | Sell |
47,427
-10,286
| -18% | -$475K | 0.03% | 505 |
|
|
2016
Q4 | $2.16M | Buy |
57,713
+1,507
| +3% | +$63.1K | 0.02% | 530 |
|
|
2016
Q3 | $3.81M | Sell |
56,206
-9,945
| -15% | -$702K | 0.05% | 298 |
|
|
2016
Q2 | $3.67M | Buy |
66,151
+1,528
| +2% | +$96.3K | 0.05% | 304 |
|
|
2016
Q1 | $4.06M | Sell |
64,623
-6,281
| -9% | -$418K | 0.06% | 278 |
|
|
2015
Q4 | $6.67M | Buy |
70,904
+3,682
| +5% | +$341K | 0.08% | 239 |
|
|
2015
Q3 | $5.4M | Sell |
67,222
-4,118
| -6% | -$458K | 0.08% | 258 |
|
|
2015
Q2 | $8.55M | Buy |
71,340
+71
| +0.1% | +$8.48K | 0.12% | 179 |
|
|
2015
Q1 | $7.44M | Buy |
71,269
+16,728
| +31% | +$1.7M | 0.09% | 236 |
|
|
2014
Q4 | $5.29M | Buy |
54,541
+12,752
| +31% | +$1.18M | 0.06% | 311 |
|
|
2014
Q3 | $3.26M | Sell |
41,789
-6,904
| -14% | -$445K | 0.04% | 451 |
|
|
2014
Q2 | $3.08M | Sell |
48,693
-61,005
| -56% | -$3.63M | 0.04% | 494 |
|
|
2014
Q1 | $7.37M | Buy |
109,698
+75,834
| +224% | +$5.87M | 0.09% | 187 |
|
|
2013
Q4 | $2.18M | Sell |
33,864
-26,359
| -44% | -$1.57M | 0.03% | 694 |
|
|
2013
Q3 | $3.85M | Buy |
60,223
+12,552
| +26% | +$626K | 0.09% | 172 |
|
|
2013
Q2 | $1.48M | Buy |
+47,671
| New | +$1.27M | 0.03% | 616 |
|
Other funds holding ALNY
ProShare Advisors's ALNY Position: Q2 2026 in Review
ProShare Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 26% in Q2 2026, selling an estimated $13.7M and leaving 128,514 shares worth $38.7M. The position accounts for 0.06% of the portfolio, ranked #180.
ProShare Advisors first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $83.9M in Q4 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- ProShare Advisors held 128,514 shares of Alnylam Pharmaceuticals worth $38.7M as of Q2 2026.
- ProShare Advisors sold 45,499 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $13.7M.
- Alnylam Pharmaceuticals made up 0.06% of ProShare Advisors's portfolio in Q2 2026, its #180 holding.
- ProShare Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- ProShare Advisors's Alnylam Pharmaceuticals position peaked at $83.9M in Q4 2025.
- 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.